{"title":"Effect of albumin in patients receiving hemodialysis on β<sub>2</sub>-microglobulin amyloid fibril formation.","authors":"Shoko Yamazaki, Keiichi Yamaguchi, Hirokazu Matsuda, Yuji Goto, Kichitaro Nakajima, Hirotsugu Ogi, Hirofumi Watanabe, Ryohei Kaseda, Isei Ei, Yutaka Kitazato, Hiroshi Watanabe, Toru Maruyama, Yoshitomi Kanemitsu, Sawako Goto, Ryota Kujirai, Yotaro Matsumoto, Yoshihisa Tomioka, Takaaki Abe, Suguru Yamamoto","doi":"10.1080/13506129.2026.2759268","DOIUrl":"https://doi.org/10.1080/13506129.2026.2759268","url":null,"abstract":"<p><strong>Background: </strong>Dialysis-related amyloidosis (DRA) involves β<sub>2</sub>-microglobulin (β2M) amyloid (Aβ2M) deposition. While albumin suppresses amyloidogenesis <i>in vitro</i>, the impact of its quality (oxidation/uremic toxin binding) in patients receiving hemodialysis (HD) remains unclear. We investigated how albumin quantity/quality in patients receiving HD affects Aβ2M fibrillogenesis.</p><p><strong>Methods: </strong>Serum from patients receiving HD (<i>n</i> = 30) and healthy individuals (<i>n</i> = 30) was incubated with β2M monomers. Fibrillogenesis was monitored <i>via</i> Thioflavin T (ThT) fluorescence. Oxidized albumin and uremic toxins were quantified using liquid chromatography-mass spectrometry.</p><p><strong>Results: </strong>Serum suppressed Aβ2M amyloid fibril formation in a concentration-dependent manner. Compared to healthy serum, HD serum showed significantly higher maximum ThT fluorescence (23.3 ± 5.2 vs. 16.2 ± 8.4 a.u., <i>p</i> < 0.001) and shorter half times (37.2 ± 10.3 vs. 51.6 ± 13.7 h, <i>p</i> < 0.001). Serum albumin levels were correlated with ThTmax (r = -0.53, <i>p</i> < 0.001) and half time (<i>r</i> = 0.59, <i>p</i> < 0.001). In multiple regression analyses, albumin concentration was independently associated with both parameters, whereas oxidized albumin and uremic toxins were not significantly associated.</p><p><strong>Conclusions: </strong>HD serum showed a reduced suppressive effect on Aβ2M amyloid fibril formation. Albumin quantity, rather than quality, primarily determines Aβ2M amyloidogenesis.</p>","PeriodicalId":50964,"journal":{"name":"Amyloid-Journal of Protein Folding Disorders","volume":" ","pages":"1-11"},"PeriodicalIF":5.1,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Longitudinal changes in gastrointestinal amyloid deposition before and after patisiran treatment in Hereditary ATTR amyloidosis.","authors":"Shinji Masuko, Mitsuto Sato, Ken Takasone, Akira Matsushima, Shin Yanagisawa, Kazuhiro Oguchi, Yusuke Mochizuki, Yusuke Takahashi, Tsuneaki Yoshinaga, Nagaaki Kato, Yoshiki Sekijima","doi":"10.1080/13506129.2026.2757148","DOIUrl":"https://doi.org/10.1080/13506129.2026.2757148","url":null,"abstract":"<p><strong>Background: </strong>Whether amyloid deposits regress after RNA interference therapy in hereditary ATTR (ATTRv) amyloidosis remains uncertain.</p><p><strong>Objective: </strong>To quantify gastrointestinal amyloid changes before and after patisiran initiation and evaluate gastric and duodenal trajectories.</p><p><strong>Methods: </strong>Twenty-six patients underwent serial gastroduodenal biopsies from up to 3 years before through 3 years after patisiran initiation. Digitally quantified submucosal Congo red (CR)-positive and transthyretin (TTR)-immunoreactive area fractions were analyzed using piecewise linear mixed-effects models with a knot at treatment initiation; categorical-year and site-stratified analyses were secondary.</p><p><strong>Results: </strong>Among 102 patient-time-point observations, CR positivity increased before patisiran (odds ratio [OR] per year, 1.87; 95% CI, 1.29-2.70) and decreased afterward (OR/year, 0.72; 95% CI, 0.55-0.94), with a significant slope change (OR ratio, 0.38; 95% CI, 0.22-0.66). At year 3, estimated CR positivity was 0.30%, compared with 1.08% at baseline (OR, 0.27; Holm-adjusted <i>p</i> = 0.0287). The TTR slope change was not significant (ratio, 0.56; <i>p</i> = 0.062). Gastric CR positivity showed a pronounced reversal (pretreatment OR/year, 3.71; post-treatment OR/year, 0.48; slope ratio, 0.13; <i>p</i> < 0.001), whereas the duodenal slope did not change significantly.</p><p><strong>Conclusion: </strong>Patisiran was associated with regression of CR-positive gastrointestinal amyloid, while TTR-immunostaining and duodenal findings suggested assay- and site-dependent heterogeneity.</p>","PeriodicalId":50964,"journal":{"name":"Amyloid-Journal of Protein Folding Disorders","volume":" ","pages":"1-11"},"PeriodicalIF":5.1,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joel N Buxbaum, David S Eisenberg, Marcus Fändrich, Ellen D McPhail, Giampaolo Merlini, Maria J M Saraiva, Stefan Schönland, Yoshiki Sekijima, Per Westermark
{"title":"Amyloid nomenclature 2026: update, novel proteins, and discussion of intracellular aggregates and toxicity. Recommendations by the International Society of Amyloidosis Nomenclature Committee.","authors":"Joel N Buxbaum, David S Eisenberg, Marcus Fändrich, Ellen D McPhail, Giampaolo Merlini, Maria J M Saraiva, Stefan Schönland, Yoshiki Sekijima, Per Westermark","doi":"10.1080/13506129.2026.2754262","DOIUrl":"https://doi.org/10.1080/13506129.2026.2754262","url":null,"abstract":"<p><p>Protein misfolding followed by aggregation into amyloid fibrils is a more common process than previously believed, and knowledge of the underlying mechanisms and their associations with disease is rapidly expanding. The International Society of Amyloidosis (ISA) has long maintained a Nomenclature Committee to meet the need for uniform terminology, amyloid protein names and abbreviations, and to harmonize these with other nomenclature systems. For this update, virtual meetings and electronic correspondence preceded the 2026 ISA meeting in Montevideo, Uruguay, resulting in the present revised document. Amyloid is defined by the beta-sheet structure of its principal fibril protein, although amyloid deposits formed <i>in vivo</i> contain additional components. The principles underlying the recommended amyloid nomenclature remain unchanged but have been further clarified. The number of known human amyloid fibril proteins associated with systemic amyloidosis remains 19. Most are linked to genetic variants and are extremely rare. In animals, nine different fibril proteins have been identified in association with systemic amyloidoses. The rapidly growing body of knowledge concerning pathological intracellular protein aggregates and their contribution to tissue vulnerability is covered in an expanded section of this paper.</p>","PeriodicalId":50964,"journal":{"name":"Amyloid-Journal of Protein Folding Disorders","volume":" ","pages":"1-11"},"PeriodicalIF":5.1,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149372017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Operational definitions of the asymptomatic <i>TTR</i> variant carrier: a methodological framework for ATTRv amyloidosis polyneuropathy research.","authors":"Isabel Conceição, José Castro, Mamede de Carvalho","doi":"10.1080/13506129.2026.2752854","DOIUrl":"https://doi.org/10.1080/13506129.2026.2752854","url":null,"abstract":"","PeriodicalId":50964,"journal":{"name":"Amyloid-Journal of Protein Folding Disorders","volume":" ","pages":"1-4"},"PeriodicalIF":5.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149327248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Robert A. Kyle: In Memoriam.","authors":"Shaji K Kumar, Morie A Gertz","doi":"10.1080/13506129.2026.2754630","DOIUrl":"https://doi.org/10.1080/13506129.2026.2754630","url":null,"abstract":"","PeriodicalId":50964,"journal":{"name":"Amyloid-Journal of Protein Folding Disorders","volume":" ","pages":"1-2"},"PeriodicalIF":5.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149327249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Camille Sarrazyn, Philippe Debonnaire, Mathias Claeys, Francesca Graziani, Maria Chiara Meucci, Erwan Donal, Madelien Regeer, Fausto Jose Pinto, Steven Droogmans, Nico Van de Veire, Philippe Bertrand, Ching Hui Sia, Arnold Ng, Ruxandra Jurcut, Robert Adam, Kensuke Hirasawa, Takeru Nabeta, Caroline Van De Heyning, Nicole Sturkenboom, Jeroen J Bax, Nina Ajmone Marsan
{"title":"Prevalence and prognostic impact of valvular heart disease in transthyretin cardiac amyloidosis.","authors":"Camille Sarrazyn, Philippe Debonnaire, Mathias Claeys, Francesca Graziani, Maria Chiara Meucci, Erwan Donal, Madelien Regeer, Fausto Jose Pinto, Steven Droogmans, Nico Van de Veire, Philippe Bertrand, Ching Hui Sia, Arnold Ng, Ruxandra Jurcut, Robert Adam, Kensuke Hirasawa, Takeru Nabeta, Caroline Van De Heyning, Nicole Sturkenboom, Jeroen J Bax, Nina Ajmone Marsan","doi":"10.1080/13506129.2026.2746736","DOIUrl":"https://doi.org/10.1080/13506129.2026.2746736","url":null,"abstract":"<p><strong>Background: </strong>Significant valvular heart disease (VHD) is associated with adverse prognosis in transthyretin amyloidosis cardiomyopathy (ATTR-CM). However, data is limited to isolated VHD. We aimed at evaluating the difference in outcome between isolated and multiple VHD, and particularly with and without aortic stenosis (AS).</p><p><strong>Methods: </strong>Patients with ATTR-CM were retrospectively included in a multicentric registry. The endpoint was a composite of heart failure hospitalizations and all-cause death.</p><p><strong>Results: </strong>Of the 694 patients (mean age 75 ± 13 years,74%male), 302(44%) presented with significant VHD. Of these, 98 had VHD including AS (isolated AS in 45%;multiple VHD with AS in 55%), while 204 had VHD without AS (isolated in 64%, multiple VHD in 36%). During a median follow-up of 22(8-38) months, 217(31%) patients reached the endpoint. Significant VHD was associated with worse outcomes than no-VHD (log-rank <i>p</i> < 0.001; HR:3.275; 95%CI (2.472-4.337), remaining significant after adjustment (HR2.006 (1.193-3.047);<i>p</i> = 0.007). Stratification by the presence of AS, and according to isolated or multiple VHD, revealed that isolated significant AS ((HR: 2.462; 95%CI (1.233-4.917); <i>p</i> = 0.011), and multiple VHD including significant AS, had the highest risk for adverse outcomes ((HR: 3.385; 95%CI (1.744-6.573);<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>In ATTR-CM, significant VHD is strongly associated with poor prognosis, with the highest risk for adverse events in significant multiple VHD including AS.</p>","PeriodicalId":50964,"journal":{"name":"Amyloid-Journal of Protein Folding Disorders","volume":" ","pages":"1-13"},"PeriodicalIF":5.1,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149302205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura Obici, Thibaud Damy, Lucia Galan, William Moody, João Agostinho, Carys Barton, Catarina Campos, Giovanni D'Alessio, Keith Dares, Maike F Dohrn, Nowell Fine, David Gregory, Emmanuel Jammes, Katharine McIntosh, Tomas Ripoll-Vera, Ali Yilmaz, Isabel Ritchie, Giovanni Palladini
{"title":"Quality standards for the diagnosis and management of ATTR and AL amyloidosis: a nominal group technique study.","authors":"Laura Obici, Thibaud Damy, Lucia Galan, William Moody, João Agostinho, Carys Barton, Catarina Campos, Giovanni D'Alessio, Keith Dares, Maike F Dohrn, Nowell Fine, David Gregory, Emmanuel Jammes, Katharine McIntosh, Tomas Ripoll-Vera, Ali Yilmaz, Isabel Ritchie, Giovanni Palladini","doi":"10.1080/13506129.2026.2743072","DOIUrl":"10.1080/13506129.2026.2743072","url":null,"abstract":"<p><strong>Background: </strong>Transthyretin (ATTR) and immunoglobulin light-chain (AL) amyloidosis are progressive conditions that can have debilitating effects on people. Delayed diagnosis and variable access to high-quality care continue to affect quality of life and prognosis. Clear and ambitious quality standards could drive consistent care and improve outcomes.</p><p><strong>Methods: </strong>A modified nominal group technique was used to develop consensus-based quality standards for the diagnosis and management of ATTR and AL amyloidosis. Eighteen experts participated, including patient representatives and clinicians from high-income, publicly funded health systems in Europe and Canada. Each quality standard was paired with at least one measurable indicator to support implementation and monitoring.</p><p><strong>Results: </strong>A total of 29 provisional statements were generated, with consensus achieved on eight quality standards. These span the full care pathway and emphasise the need for timely, person-centred and interdisciplinary care. Twenty accompanying indicators were developed.</p><p><strong>Conclusion: </strong>This is the first comprehensive set of consensus-based quality standards for ATTR and AL amyloidosis care. They provide a practical and aspirational framework to guide quality improvement across health systems. Adoption of these standards could improve early diagnosis, equitable access to treatment, and quality of life. Future research may explore their feasibility and adaptation for other health system settings.</p>","PeriodicalId":50964,"journal":{"name":"Amyloid-Journal of Protein Folding Disorders","volume":" ","pages":"1-15"},"PeriodicalIF":5.1,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149231084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Navid Noory, Peter L Graversen, Eva Havers-Borgersen, Oscar Westin, Mathew S Maurer, Kasper Rossing, Lars Køber, Finn Gustafsson, Emil Fosbøl
{"title":"Multiple musculoskeletal procedures over time and the risk of amyloidosis: a Danish nationwide cohort study.","authors":"Navid Noory, Peter L Graversen, Eva Havers-Borgersen, Oscar Westin, Mathew S Maurer, Kasper Rossing, Lars Køber, Finn Gustafsson, Emil Fosbøl","doi":"10.1080/13506129.2026.2748887","DOIUrl":"https://doi.org/10.1080/13506129.2026.2748887","url":null,"abstract":"","PeriodicalId":50964,"journal":{"name":"Amyloid-Journal of Protein Folding Disorders","volume":" ","pages":"1-4"},"PeriodicalIF":5.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149229335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Full-length light chain sequencing refocuses attention on the constant domain in AL amyloidosis.","authors":"Luis Del Pozo-Yauner","doi":"10.1080/13506129.2026.2747712","DOIUrl":"https://doi.org/10.1080/13506129.2026.2747712","url":null,"abstract":"","PeriodicalId":50964,"journal":{"name":"Amyloid-Journal of Protein Folding Disorders","volume":" ","pages":"1-3"},"PeriodicalIF":5.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}